Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4077133
Max Phase: Preclinical
Molecular Formula: C21H23FN2O4
Molecular Weight: 386.42
Molecule Type: Small molecule
Associated Items:
ID: ALA4077133
Max Phase: Preclinical
Molecular Formula: C21H23FN2O4
Molecular Weight: 386.42
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CNC(=O)c1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F
Standard InChI: InChI=1S/C21H23FN2O4/c1-23-21(25)17-8-13(2-4-18(17)22)16-6-7-24-10-14(16)11-26-15-3-5-19-20(9-15)28-12-27-19/h2-5,8-9,14,16,24H,6-7,10-12H2,1H3,(H,23,25)/t14-,16-/m0/s1
Standard InChI Key: QPYISJMTYHPQCR-HOCLYGCPSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 386.42 | Molecular Weight (Monoisotopic): 386.1642 | AlogP: 2.69 | #Rotatable Bonds: 5 |
Polar Surface Area: 68.82 | Molecular Species: BASE | HBA: 5 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 13.16 | CX Basic pKa: 9.76 | CX LogP: 2.22 | CX LogD: -0.08 |
Aromatic Rings: 2 | Heavy Atoms: 28 | QED Weighted: 0.83 | Np Likeness Score: -0.46 |
1. Waldschmidt HV, Homan KT, Cato MC, Cruz-Rodríguez O, Cannavo A, Wilson MW, Song J, Cheung JY, Koch WJ, Tesmer JJ, Larsen SD.. (2017) Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors Based on Paroxetine., 60 (7): [PMID:28323425] [10.1021/acs.jmedchem.7b00112] |
Source(1):